Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer

European Journal of Cancer

Volumn 50, Issue 9, 2014, Pages 1590-1601

  Jones, Robert P ^a,b   Hamann, Susanne ^c   Malik, Hassan Z ^b   Fenwick, Stephen W ^b   Poston, Graeme J ^b   Folprecht, Gunnar ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Chemotherapy; Colorectal; Liver; Metastases; RECIST; Resection; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SIZE; COLORECTAL LIVER METASTASIS; DISEASE SEVERITY; HUMAN; LIVER BLOOD VESSEL; LIVER RESECTION; MEDICAL SPECIALIST; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MINIMAL RESIDUAL DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGEON; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

CHEMOTHERAPY; COLORECTAL; LIVER; METASTASES; RECIST; RESECTION; SURGERY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84901232014     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.02.024     Document Type: Article

References (57)

1. P. Rougier, C. Milan, F. Lazorthes, G. Fourtanier, C. Partensky, and H. Baumel et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Fondation Française de Cancérologie Digestive Br J Surg 82 10 1995 1397 1400
2. J. Scheele, R. Stang, A. Altendorf-Hofmann, and M. Paul Resection of colorectal liver metastases World J Surg 19 1 1995 59 71
3. R. Adam, and E. Vinet Regional treatment of metastasis: surgery of colorectal liver metastases Ann Oncol 15 Suppl. 4 2004 iv103 iv106
4. V.W.T. Lam, C. Spiro, J.M. Laurence, E. Johnston, M.J. Hollands, and H.C.C. Pleass et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases Ann Surg Oncol 19 4 2012 1292 1301
5. G. Folprecht, A. Grothey, S. Alberts, H.-R. Raab, and C.-H. Köhne Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates Ann Oncol 16 8 2005 1311 1319
6. E. Van Cutsem, C.-H. Köhne, E. Hitre, J. Zaluski, C.-R. Chang Chien, and A. Makhson et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
7. G. Masi, F. Loupakis, L. Salvatore, L. Fornaro, C. Cremolini, and S. Cupini et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial Lancet Oncol 11 9 2010 845 852
8. Y.S. Chun, J.-N. Vauthey, P. Boonsirikamchai, D.M. Maru, S. Kopetz, and M. Palavecino et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases JAMA 302 21 2009 2338 2344
9. L.B. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer, A. Figer, and R. Wong et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 12 2008 2013 2019
10. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Int J Surg 8 5 2010 336 341
11. R. Zhao, J. Zhu, X. Ji, J. Cai, F. Wan, and Q. Li et al. A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer Jpn J Clin Oncol 40 1 2010 10 16
12. B.S. Min, N.K. Kim, J.B. Ahn, J.K. Roh, K.S. Kim, and J.S. Choi et al. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases Onkologie 30 12 2007 637 643
13. W.M. Ho, B. Ma, T. Mok, W. Yeo, P. Lai, and R. Lim et al. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group Med Oncol 22 3 2005 303 312
14. M. Ychou, F. Viret, A. Kramar, F. Desseigne, E. Mitry, and R. Guimbaud et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases Cancer Chemother Pharmacol 62 2 2008 195 201
15. J. De La Cámara, J. Rodriguez, F. Rotellar, A. Viudez, J. García-Foncillas, and F. Pardo et al. Triplet therapy with oxaliplatin, irinotecan, 5-fFu and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer J Clin Oncol 23 2004 [abstr. 3593]
16. T. Beppu, N. Hayashi, T. Masuda, H. Komori, K. Horino, and H. Hayashi et al. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases Anticancer Res 30 3 2010 1015 1020
17. Y. Shibata Multicentre phase II study of FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study Ann Oncol 21 Suppl. 8 2010 [abstr. 3518]
18. R. Wong, D. Cunningham, Y. Barbachano, C. Saffery, J. Valle, and T. Hickish et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection Ann Oncol 22 9 2011 2042 2048
19. T. Takahashi, Y. Shibata, Y. Tojima, K. Tsuboi, E. Sakamoto, and K. Kunieda et al. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study Int J Clin Oncol 2012
20. C. Garufi, A. Torsello, S. Tumolo, G.M. Ettorre, M. Zeuli, and C. Campanella et al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial Br J Cancer 103 10 2010 1542 1547
21. G. Masi, G. Allegrini, S. Cupini, L. Marcucci, E. Cerri, and I. Brunetti et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule Ann Oncol 15 12 2004 1766 1772
22. E. Skof, M. Rebersek, Z. Hlebanja, and J. Ocvirk Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial BMC Cancer 9 2009 120 10.1186/1471-2407-9-120
23. L.-C. Ye, T.-S. Liu, L. Ren, Y. Wei, D.-X. Zhu, and S.-Y. Zai et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases J Clin Oncol 31 16 2013 1931 1938
24. G. Folprecht, M.P. Lutz, P. Schöffski, T. Seufferlein, A. Nolting, and P. Pollert et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma Ann Oncol 17 3 2006 450 456
25. U. Tirelli, M. Berretta, F. Di Benedetto, E. Zanet, A. Bearz, and A. Lleshi et al. Presurgical chemotherapy with FOLFOX4 regimen for patients with unresectable liver metastases from colorectal cancer J Clin Oncol 26 15 2008 [abstr. 52]
26. S.R. Alberts, W.L. Horvath, W.C. Sternfeld, R.M. Goldberg, M.R. Mahoney, and S.R. Dakhil et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study J Clin Oncol 23 36 2005 9243 9249
27. C. Pozzo, M. Basso, A. Cassano, M. Quirino, G. Schinzari, and N. Trigila et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients Ann Oncol 15 6 2004 933 939
28. L. Zelek, R. Bugat, D. Cherqui, G. Ganem, P. Valleur, and R. Guimbaud et al. Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial) Ann Oncol 14 10 2003 1537 1542
29. S. Giacchetti, M. Itzhaki, G. Gruia, R. Adam, R. Zidani, and F. Kunstlinger et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery Ann Oncol 10 6 1999 663 669
30. M. Ychou, M. Rivoire, S. Thezenas, F. Quenet, J.-R. Delpero, and C. Rebischung et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial Ann Surg Oncol 20 13 2013 4289 4297
31. G. Folprecht, T. Gruenberger, W.O. Bechstein, H.-R. Raab, F. Lordick, and J.T. Hartmann et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial Lancet Oncol 11 1 2010 38 47
32. C. Bokemeyer, I. Bondarenko, J.T. Hartmann, F. de Braud, G. Schuch, and A. Zubel et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study Ann Oncol 22 7 2011 1535 1546
33. J.-Y. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, and M. Barugel et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 31 2010 4697 4705
34. T.S. Maughan, R.A. Adams, C.G. Smith, A.M. Meade, M.T. Seymour, and R.H. Wilson et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial Lancet 377 9783 2011 2103 2114
35. A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, and C. Barbara et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest J Clin Oncol 25 13 2007 1670 1676
36. G.J. Poston, R. Adam, S. Alberts, S. Curley, J. Figueras, and D. Haller et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer J Clin Oncol 23 28 2005 7125 7134
37. R. Adam, A. De Gramont, J. Figueras, A. Guthrie, N. Kokudo, and F. Kunstlinger et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus Oncologist 17 10 2012 1225 1239
38. E. Van Cutsem, B. Nordlinger, R. Adam, C.-H. Köhne, C. Pozzo, and G. Poston et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases Eur J Cancer 42 14 2006 2212 2221
39. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
40. C. Bokemeyer, I. Bondarenko, A. Makhson, J.T. Hartmann, J. Aparicio, and F. de Braud et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 5 2009 663 671
41. C.-H. Kohne Efficacy of chemotherapy and cetuximab according to metastatic site in KRAS wild type metastatic colorectal cancer: analysis of CRYSTAL and OPUS studies Ann Oncol 22 Suppl. 5 2011 [abstr. O-0002]
42. V. Heinemann Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizuman as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3) J Clin Oncol 31 LBA3506 2013 [abstr. 3506]
43. S. Schwartzberg PEAK (study 20070509): a randomized phase II study of mFOLFOX6 with either panitumumab or bevacizumab as first-line treatment in patients with unresectable wildtype KRAS metastatic colorectal cancer J Clin Oncol 30 Suppl. 34 2013 [abstr. 446]
44. R.P. Jones, J.-N. Vauthey, R. Adam, M. Rees, D. Berry, and R. Jackson et al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases Br J Surg 99 9 2012 1263 1269
45. G.P. Kanas, A. Taylor, J.N. Primrose, W.J. Langeberg, M.A. Kelsh, and F.S. Mowat et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors Clin Epidemiol 4 2012 283 301 10.2147/CLEP.S34285
46. L. Spelt, B. Andersson, J. Nilsson, and R. Andersson Prognostic models for outcome following liver resection for colorectal cancer metastases: a systematic review Eur J Surg Oncol 38 1 2012 16 24
47. T. Treasure, L. Fallowfield, B. Lees, and V. Farewell Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial Thorax 67 2 2012 185 187
48. C. Garufi, A. Torsello, S. Tumolo, M. Mottolese, C. Campanella, and M. Zeuli et al. POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP)(CPT-11-FFL) in unresectable colorectal liver metastases (CLM) J Clin Oncol (Meeting Abstracts) 27 15 Suppl. 2009 [abstr. 20]
49. C. Garufi, A. Torsello, C. Campanella, G.M. Ettorre, G. Vennarecci, and E. Melucci et al. CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP)(CPT-11-FFL) plus cetuximab (Cmab) in unselected advanced colorectal cancer (ACC) patients J Clin Oncol (Meeting Abstracts) 28 15 suppl. 2010 [abstr. 3551]
50. S. Stintzing, L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, E. Jäger, and T. Heintges et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306 Ann Oncol 23 7 2012 1693 1699
51. Hofheinz R, Mineur L, Greil C. Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): resections and curative surgery in a phase II single arm, multicenter study (20060314). ASCO Annual Meeting Proceedings; 2010.
52. K. Uehara, S. Ishiguro, K. Hiramatsu, H. Nishio, E. Takeuchi, and D. Takahari et al. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer Jpn J Clin Oncol 41 10 2011 1229 1232
53. F. Lévi, A. Karaboué, L. Gorden, P.F. Innominato, R. Saffroy, and S. Giacchetti et al. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability Cancer Chemother Pharmacol 67 2 2011 339 348
54. O.F. Bathe, S. Ernst, F.R. Sutherland, E. Dixon, C. Butts, and D. Bigam et al. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases BMC Cancer 9 2009 156 10.1186/1471-2407-9-156
55. B. Gruenberger, D. Tamandl, J. Schueller, W. Scheithauer, C. Zielinski, and F. Herbst et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J Clin Oncol 26 11 2008 1830 1835
56. S. Radic Prospective evaluation of efficacy and safety of bevacizumab therapy in metastatic colorectal carcinoma; interim analysis of resectability rate Ann Oncol 21 8 2010 217
57. E. Terrebonne, D. Smith, Y. Becouarn, P. Michel, R. Guimbaud, and D. Auby et al. Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: results of the ETNA cohort study J Clin Oncol (Meeting Abstracts) 28 15 Suppl. 2010 [abstr. 3594]